Status:
COMPLETED
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Lead Sponsor:
Genentech, Inc.
Conditions:
Ovarian Cancer
Basal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismod...
Eligibility Criteria
Inclusion
- This study only enrolled participants who took part in previous studies of vismodegib conducted by Genentech.
- Completed vismodegib treatment within 2-4 weeks in a Genentech-sponsored parent study or continued to receive vismodegib at the time the Genentech-sponsored parent study closed.
- Expectation by the investigator that the participant may continue to benefit from additional vismodegib treatment.
Exclusion
- Intervening anti-tumor therapy not specified in the parent study (ie, non-protocol-specified chemotherapy, other targeted therapy, radiation therapy, or photodynamic therapy).
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00959647
Start Date
September 1 2009
End Date
January 1 2014
Last Update
January 7 2015
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Scottsdale, Arizona, United States, 85258
2
Oakland, California, United States, 94609
3
Palm Springs, California, United States, 92262
4
Stanford, California, United States, 94305